338 related articles for article (PubMed ID: 33268854)
21. Salvage radiotherapy in patients affected by oligorecurrent pelvic nodal prostate cancer.
Ingrosso G; Mariucci C; Tenti MV; Bini V; Alì E; Saldi S; Palumbo I; Bellavita R; Aristei C
Clin Transl Oncol; 2020 Dec; 22(12):2236-2243. PubMed ID: 32418156
[TBL] [Abstract][Full Text] [Related]
22. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.
Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol; 2020 Dec; 78(6):779-782. PubMed ID: 32624281
[TBL] [Abstract][Full Text] [Related]
23. SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
Rans K; Charlien B; Filip A; Olivier H; Julie DH; Céderic D; Herlinde D; Benedikt E; Karolien G; Annouschka L; Nick L; Kenneth P; Carl S; Koen S; Hans V; Ben V; Steven J; Gert M
BMC Cancer; 2022 Dec; 22(1):1294. PubMed ID: 36503429
[TBL] [Abstract][Full Text] [Related]
24. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
25. Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy.
Devos G; Berghen C; Van Eecke H; Stichele AV; Van Poppel H; Goffin K; Mai C; De Wever L; Albersen M; Everaerts W; De Meerleer G; Joniau S
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32823690
[TBL] [Abstract][Full Text] [Related]
26. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.
Boorjian SA; Karnes RJ; Viterbo R; Rangel LJ; Bergstralh EJ; Horwitz EM; Blute ML; Buyyounouski MK
Cancer; 2011 Jul; 117(13):2883-91. PubMed ID: 21692049
[TBL] [Abstract][Full Text] [Related]
27. Salvage lymph node dissection in patients with prostate cancer treated with radical prostatectomy or radiotherapy and positive choline positron emission tomography (PET/CT) scan.
Otta-Oshiro RJ; Lista-Mateos F; García-Mediero J; Arranz-Arija JA; García-Prado J; Núñez-Mora C
Actas Urol Esp (Engl Ed); 2019; 43(6):331-335. PubMed ID: 30975547
[TBL] [Abstract][Full Text] [Related]
28. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
29. Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factors.
Poelaert F; Fonteyne V; Ost P; De Troyer B; Decaestecker K; De Meerleer G; De Visschere P; Claeys T; Dhondt B; Lumen N
Strahlenther Onkol; 2017 Jun; 193(6):444-451. PubMed ID: 28101585
[TBL] [Abstract][Full Text] [Related]
30. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.
Ost P; Siva S; Brabrand S; Dirix P; Liefhooghe N; Otte FX; Gomez-Iturriaga A; Everaerts W; Shelan M; Conde-Moreno A; López Campos F; Papachristofilou A; Guckenberger M; Scorsetti M; Zapatero A; Villafranca Iturre AE; Eito C; Couñago F; Muto P; Van De Voorde L; Mach N; Bultijnck R; Fonteyne V; Moon D; Thon K; Mercier C; Achard V; Stellamans K; Goetghebeur E; Reynders D; Zilli T
Eur Urol Oncol; 2024 Jun; 7(3):462-468. PubMed ID: 37821242
[TBL] [Abstract][Full Text] [Related]
31. PSMA-positive nodal recurrence in prostate cancer : Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis.
Schmidt-Hegemann NS; Buchner A; Eze C; Rogowski P; Schaefer C; Ilhan H; Li M; Fendler WP; Bartenstein P; Ganswindt U; Stief C; Belka C; Kretschmer A
Strahlenther Onkol; 2020 Jul; 196(7):637-646. PubMed ID: 32211942
[TBL] [Abstract][Full Text] [Related]
32. Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study.
Kim M; Song C; Jeong IG; Choi SK; Park M; Shim M; Kim YS; You D; Hong JH; Kim CS; Ahn H
BMC Cancer; 2018 Mar; 18(1):271. PubMed ID: 29523103
[TBL] [Abstract][Full Text] [Related]
33. Sentinel Lymph Node Dissection to Select Clinically Node-negative Prostate Cancer Patients for Pelvic Radiation Therapy: Effect on Biochemical Recurrence and Systemic Progression.
Grivas N; Wit E; Pos F; de Jong J; Vegt E; Bex A; Hendricksen K; Horenblas S; KleinJan G; van Rhijn B; van der Poel H
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):347-354. PubMed ID: 28068243
[TBL] [Abstract][Full Text] [Related]
34. OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.
Supiot S; Vaugier L; Pasquier D; Buthaud X; Magné N; Peiffert D; Sargos P; Crehange G; Pommier P; Loos G; Hasbini A; Latorzeff I; Silva M; Denis F; Lagrange JL; Morvan C; Campion L; Blanc-Lapierre A
Eur Urol; 2021 Oct; 80(4):405-414. PubMed ID: 34247896
[TBL] [Abstract][Full Text] [Related]
35. Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: Perioperative and early oncological outcomes.
Linxweiler J; Saar M; Al-Kailani Z; Janssen M; Ezziddin S; Stöckle M; Siemer S; Ohlmann CH
Surg Oncol; 2018 Jun; 27(2):138-145. PubMed ID: 29937163
[TBL] [Abstract][Full Text] [Related]
36. Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy.
Wenzel M; Garcia CC; Hoeh B; Jorias C; Humke C; Koll F; Tselis N; Rödel C; Graefen M; Tilki D; Chun FKH; Mandel P
Prostate; 2023 Oct; 83(14):1365-1372. PubMed ID: 37464963
[TBL] [Abstract][Full Text] [Related]
37. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.
Ost P; Bossi A; Decaestecker K; De Meerleer G; Giannarini G; Karnes RJ; Roach M; Briganti A
Eur Urol; 2015 May; 67(5):852-63. PubMed ID: 25240974
[TBL] [Abstract][Full Text] [Related]
38. Management of positive lymph nodes following radical prostatectomy.
Heidenreich A; Rieke M; Mahjoub S; Pfister D
Arch Esp Urol; 2019 Mar; 72(2):182-191. PubMed ID: 30855020
[TBL] [Abstract][Full Text] [Related]
39. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D;
Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
[TBL] [Abstract][Full Text] [Related]
40. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]